These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 15038947

  • 1. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 2. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 4. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J, Vanuga P, Payer J, Svobodník A.
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [Abstract] [Full Text] [Related]

  • 5. Compliance of osteoporotic patients with different treatment regimens.
    Segal E, Tamir A, Ish-Shalom S.
    Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
    Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE.
    Menopause; 2004 Dec; 11(4):405-15. PubMed ID: 15243278
    [Abstract] [Full Text] [Related]

  • 7. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
    Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH.
    Osteoporos Int; 2008 Jul; 19(7):1055-65. PubMed ID: 18283386
    [Abstract] [Full Text] [Related]

  • 8. Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
    Akbaba G, Isik S, Ates Tutuncu Y, Ozuguz U, Berker D, Guler S.
    J Endocrinol Invest; 2013 Dec; 36(11):1076-82. PubMed ID: 24081023
    [Abstract] [Full Text] [Related]

  • 9. Determinants of adherence to osteoporosis treatment in clinical practice.
    Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group.
    Osteoporos Int; 2006 Dec; 17(6):914-21. PubMed ID: 16538553
    [Abstract] [Full Text] [Related]

  • 10. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL.
    Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
    [Abstract] [Full Text] [Related]

  • 11. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.
    Osteoporos Int; 1999 Apr; 10(4):330-6. PubMed ID: 10692984
    [Abstract] [Full Text] [Related]

  • 12. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C.
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [Abstract] [Full Text] [Related]

  • 13. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.
    J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
    [Abstract] [Full Text] [Related]

  • 14. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 15. A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study.
    Minisola S, Vargas AP, Letizia Mauro G, Bonet Madurga F, Adami G, Black DM, Qizilbash N, Blanch-Rubió J.
    JBMR Plus; 2021 Jul; 5(7):e10510. PubMed ID: 34258506
    [Abstract] [Full Text] [Related]

  • 16. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
    Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D.
    J Bone Miner Metab; 2007 Jul; 25(2):105-13. PubMed ID: 17323180
    [Abstract] [Full Text] [Related]

  • 17. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D.
    JAMA; 2000 Mar 08; 283(10):1318-21. PubMed ID: 10714731
    [Abstract] [Full Text] [Related]

  • 18. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
    Ringe JD, Christodoulakos GE, Mellström D, Petto H, Nickelsen T, Marín F, Pavo I.
    Curr Med Res Opin; 2007 Nov 08; 23(11):2677-87. PubMed ID: 17883882
    [Abstract] [Full Text] [Related]

  • 19. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.
    Mosca L, Harper K, Sarkar S, O'Gorman J, Anderson PW, Cox DA, Barrett-Connor E.
    Clin Ther; 2001 Sep 08; 23(9):1552-65. PubMed ID: 11589267
    [Abstract] [Full Text] [Related]

  • 20. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H.
    J Bone Miner Res; 2014 Aug 08; 29(8):1777-85. PubMed ID: 24619763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.